De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sensorion Toekomstige groei

Future criteriumcontroles 2/6

De winst van Sensorion zal naar verwachting dalen met 31.5% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 49.8% per jaar. De winst per aandeel zal naar verwachting afnemen met 15.4% per jaar.

Belangrijke informatie

-31.5%

Groei van de winst

-15.4%

Groei van de winst per aandeel

Biotechs winstgroei	35.6%
Inkomstengroei	49.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	24 Sep 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:RFM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	8	-46	N/A	N/A	2
12/31/2025	14	-41	-44	-43	3
12/31/2024	16	-23	-17	-17	3
6/30/2024	6	-24	-23	-23	N/A
3/31/2024	6	-23	-22	-22	N/A
12/31/2023	6	-22	-21	-21	N/A
9/30/2023	6	-23	-22	-21	N/A
6/30/2023	6	-23	-23	-22	N/A
3/31/2023	5	-23	-23	-22	N/A
12/31/2022	5	-23	-23	-21	N/A
9/30/2022	5	-22	-19	-18	N/A
6/30/2022	5	-21	-15	-14	N/A
3/31/2022	4	-18	-13	-13	N/A
12/31/2021	4	-15	-11	-11	N/A
9/30/2021	4	-13	-12	-11	N/A
6/30/2021	3	-11	-13	-12	N/A
3/31/2021	3	-10	-9	-9	N/A
12/31/2020	2	-9	-5	-5	N/A
9/30/2020	2	-10	-8	-8	N/A
6/30/2020	2	-11	-11	-11	N/A
3/31/2020	2	-12	-12	-12	N/A
12/31/2019	2	-12	-14	-14	N/A
9/30/2019	2	-12	-12	-12	N/A
6/30/2019	2	-12	-9	-9	N/A
3/31/2019	2	-12	-11	-11	N/A
12/31/2018	2	-12	-13	-12	N/A
9/30/2018	2	-12	-11	-11	N/A
6/30/2018	2	-11	-10	-9	N/A
3/31/2018	2	-10	N/A	-9	N/A
12/31/2017	2	-10	N/A	-8	N/A
9/30/2017	1	-9	N/A	N/A	N/A
6/30/2017	0	-8	N/A	N/A	N/A
3/31/2017	0	-8	N/A	N/A	N/A
12/31/2016	0	-7	N/A	N/A	N/A
9/30/2016	0	-7	N/A	N/A	N/A
6/30/2016	1	-7	N/A	-8	N/A
3/31/2016	0	-6	N/A	-6	N/A
12/31/2015	0	-4	N/A	-5	N/A
9/30/2015	0	-4	N/A	N/A	N/A
6/30/2015	0	-3	N/A	-3	N/A
3/31/2015	0	-3	N/A	-3	N/A
12/31/2014	0	-3	N/A	-2	N/A
12/31/2013	0	-2	N/A	N/A	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat RFM de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat RFM de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat RFM de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van RFM ( 49.8% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.4% per jaar).

Hoge groei-inkomsten: De omzet van RFM ( 49.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van RFM naar verwachting over 3 jaar hoog zal zijn

Sensorion Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

First half 2024 earnings released

Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

New major risk - Revenue and earnings growth

Sensorion SA, Annual General Meeting, May 29, 2024

Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million.

Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation

Sensorion SA to Report Fiscal Year 2023 Results on Mar 14, 2024

Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation

Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors

Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries

Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer

Sensorion SA, Annual General Meeting, Dec 20, 2023

New minor risk - Market cap size

Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC

Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC

Sensorion SA to Report Q2, 2023 Results on Sep 18, 2023

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk

Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study

Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Less than half of directors are independent

Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the Treatment of Otoferlin Gene-Mediated Hearing Loss

Sensorion SA Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA to Report First Half, 2022 Results on Sep 22, 2022

Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA, Annual General Meeting, May 31, 2022

Less than half of directors are independent

Sensorion SA to Report Fiscal Year 2021 Results on Oct 31, 2022

Sensorion SA Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss

First half 2021 earnings released

Sensorion Announces Regulators Approval for Sensorion’s Amendment to Phase 2 Audible-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss

Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination with Cochlear Implantation

Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021

Sensorion Announces Third Gene Therapy Collaboration with Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven